Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

23,580 signal articles · 332 in last 24h · 112,379 total before filter · latest 39m ago
332last 24h
2138last 7d
376● bullish (7d)
188● bearish (7d)
204publishers
AllMacro294Earnings1216M&A91Regulatory23Product13Analyst20
✕ clear all filtersticker: MRKSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Merck (MRK) Could Be 3% Undervalued On Raised Outlook And Key Drug Approvals
Simply Wall St.5d agoneutral
Merck (MRK) Could Be 3% Undervalued On Raised Outlook And Key Drug Approvals

Merck (MRK) is back in focus after a run of product and earnings headlines. Fresh approvals and label expansion efforts for KEYTRUDA and ENFLONSIA now sit alongside a raised 2026 revenue outlook and recent acquisition charges. See our latest analysis for Merck. Merck’s share price has moved to US$128.37 after a strong run, with a 90 day share price return of 15.25% and a 1 year total shareholder return of 65.06%, suggesting momentum has been building as approvals, trial readouts and raised...

MRK
H.C. Wainwright Maintains Buy Rating on Tempus AI (TEM) Following Strong Revenue Growth
Insider Monkey71d agobullish
H.C. Wainwright Maintains Buy Rating on Tempus AI (TEM) Following Strong Revenue Growth

Tempus AI, Inc. (NASDAQ:TEM) ranks among the best short squeeze stocks to invest in. Following the company’s first-quarter results, H.C. Wainwright reduced its price target for Tempus AI, Inc. (NASDAQ:TEM) to $64 from $95 while retaining a Buy rating on the company’s shares. Tempus AI, Inc. (NASDAQ:TEM) posted total revenue of $348.1 million in Q1, […]

GILDMRKTEM
Analyst Reinstates Merck (MRK) with ‘Neutral’ Rating, $125 Price Target
Insider Monkey92d agoneutral
Analyst Reinstates Merck (MRK) with ‘Neutral’ Rating, $125 Price Target

With an annual dividend yield of 3.06%, Merck & Co., Inc. (NYSE:MRK) is included among the 12 Best Blue Chip Dividend Stocks to Buy Now. Merck & Co., Inc. (NYSE:MRK) is a global health care company working to deliver innovative health solutions through our medicines, vaccines, biologic therapies, and animal health products. On May 7, Citi analyst […]

MRK
Analyst Raises Merck (MRK) Price Target by $1 After Beating Q1 Estimates
Insider Monkey98d agobullish
Analyst Raises Merck (MRK) Price Target by $1 After Beating Q1 Estimates

With an upside potential of 21.26% as of May 3, Merck & Co., Inc. (NYSE:MRK) is included among the 10 Best Fortune 500 Stocks to Buy According to Analysts. Merck & Co., Inc. (NYSE:MRK) is a global health care company working to deliver innovative health solutions through our medicines, vaccines, biologic therapies, and animal health products. […]

MRK